ASCO 2024 Highlights Part 2

Podcast | English | 2024 | 49 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the phase III CROWN trial, ROS1 NSCLC with a novel ROS1 TKI, taletrectinib, the MARIPOSA trial, the PALOMA-3 trial, the WU-KONG1 data, the BEAMION-Lung1 trial, and CheckMate 77T.

Podcast Hosts:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA
Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Clarissa Mathias, MD, PhD, Medical Oncologist, NOB/Oncoclinicas Hospital Santa Izabel; ASCO International Quality Steering Group; President Brazilian Society of Clinical Oncology, Salvador Bahia, Brazil
Delvys Rogriquez-Abreu, MD, Head of Medical Oncology, Hospital Universitario Insular de Gran Canaria; President of the Canarian Lung Cancer Foundation, Las Palmas, Spain